The COVID-19 vaccine developed by British drugmaker AstraZeneca in conjunction with Oxford University is likely to be authorised for emergency use in the United States by April, the chief adviser for the US vaccine program says. The vaccine was on Wednesday cleared for use in the UK, with the European Union also expected to expedite authorisation. Operation Warp Speed chief adviser Dr Moncef Slaoui said recruitment for the British drugmaker's late-stage US trial is almost complete with more than 29,000 participants already enrolled. "We project, if everything goes well with readout and emergency use, authorisation may be granted somewhere in April," Slaoui said. Australian Associated Press
AstraZeneca has developed its new COVID-19 vaccine in conjunction with Oxford University in the UK.
The COVID-19 vaccine developed by British drugmaker AstraZeneca in conjunction with Oxford University is likely to be authorised for emergency use in the United States by April, the chief adviser for the US vaccine program says.
The vaccine was on Wednesday cleared for use in the UK, with the European Union also expected to expedite authorisation.
Operation Warp Speed chief adviser Dr Moncef Slaoui said recruitment for the British drugmaker's late-stage US trial is almost complete with more than 29,000 participants already enrolled.
"We project, if everything goes well with readout and emergency use, authorisation may be granted somewhere in April," Slaoui said.
Australian Associated Press
Follow us
Ad blocker issue
Your ad blocker may be preventing you from
being able to log in or subscribe.
